Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    ZOETIS

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    SERVICES

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital content

    Create Content with PharmaCompass, ask us

    INTERVIEW #SpeakPharma

    [Sponsored by another company]
    “Over 500 million syringes of our hyaluronic acid have been safely used worldwide”

    mic“Over 500 million syringes of our hyaluronic acid have been safely used worldwide”

    This week, SpeakPharma interviews Marie-Armelle Floc’h, Chief of Quality and Regulatory Affairs at HTL Biotechnology, a global leader in the development and the manufacturing of pharmaceutical-grade biopolymers headquartered in Javené, Brittany (France). Since 1992, HTL has pioneered the production of hyaluronic acid (HA) through proprietary biofermentation, achieving unmatched purity and consistency for applications in ophthalmology, dermatology and rheumatology. Floc’h highlights how HTL Biotechnology’s compelling portfolio of pharmaceutical-grade biopolymers is built on uncompromising quality standards. These standards have enabled the company to supply biopolymers for over 30 years without a single batch recall, firmly establishing its reputation for reliability and excellence. She also discusses the inauguration of HTL Biotechnology’s new sterile hyaluronic acid production unit — a major milestone that reinforces the company’s leadership in biopolymer manufacturing and enables the development of innovative formulations combining hyaluronic acid with thermo-sensitive active ingredients. This new capability opens the door to advanced biomedical applications where safety, stability and efficacy must be preserved without compromising the integrity of delicate molecules and which requires the highest quality standards. What distinguishes HTL Biotechnology’s biopolymer platforms in the market today? HTL Biotechnology has built its reputation on delivering pharmaceutical‑grade biopolymers (hyaluronic acid, polynucleotides and recombinant collagen) with unmatched purity and consistency. Since its founding in 1992, the company has focused on premium quality positioning. With more than 30 years of experience, HTL Biotechnology guarantees pharmaceutical-grade biopolymers of exceptional purity and exemplary consistency to our clients. We have had no batch recalls in 30 years, a record that underlines the rigor and reliability embedded in our processes. This was made possible by our fully-integrated site in France, where R&D laboratories, GMP manufacturing, quality control, and regulatory expertise are brought together under one roof. Such integration allows us to support our clients seamlessly throughout their product development journey, from early innovation through to global commercialization.Also, the inauguration of our new sterile hyaluronic acid production unit expands the possibilities for our HA to be used in advanced formulations with thermo-sensitive active ingredients, while upholding the uncompromising quality that defines HTL Biotechnology.Our operations are guided by internationally recognized standards, including ISO 13485 certification, which ensures the quality and safety required by medical device manufacturers worldwide.In addition, our Halal certification provides our customers with a significant advantage in accessing and expanding into markets where these requirements are essential for commercialization.Beyond certifications, our commitment to supporting global growth is reflected in the Drug Master Files we maintain across five continents, enabling our clients to accelerate product registration and bring innovative therapies to markets across the world more efficiently. By combining craftsmanship with pharmaceutical rigor, supported by state-of-the-art equipment and advanced bio-production methods, we ensure that every batch produced not only meets the strictest standards, but also delivers the reliability and consistency needed across the entire healthcare ecosystem. HIGHLIGHTS// Biopolymers with unmatched purity/record of no batch recalls/integrated facility in France/operations guided by global standards/new sterile HA unit for advanced formulations  Navigating the complex and evolving regulatory frameworks across global markets can be challenging for healthcare companies. Can you tell us more about how HTL Biotechnology supports its partners in this area? Regulatory support is part of our core premium services offer. We provide pharmaceutical regulatory support to ensure products meet the necessary compliance standards, so our partners can focus on their growth. Our dedicated regulatory professionals bring global and regional expertise, with a team specifically supporting customers in Asia. We offer personalized assistance adapted to their products and to the compliance standards of the target market. This includes personalized case-management support for regulatory file submissions with the concerned health authorities to minimize risks of refusal or delay, with the aim of achieving approval quickly and smoothly.Our offer for regulatory support continues beyond approval. We continuously monitor updates to regulations and provide post-commercialization support to our partners to help them manage any necessary regulatory updates.HIGHLIGHTS// Regulatory support offered as premium service/global and regional expertise/personalized case management for faster approvals/continuous regulatory support  How does HTL Biotechnology integrate sustainability and corporate responsibility into its operations? Sustainability is embedded in HTL Biotechnology’s strategic vision and day-to-day operations. In 2024, the company renewed its commitment to environmental responsibility by reinforcing its corporate social responsibility (CSR) roadmap. Tangible progress was made across multiple fronts: a 27 percent reduction in greenhouse gas emissions per kilogram of HA produced between 2021 and 2024, and a 34 percent reduction in water consumption per kilogram of HA since 2020. In 2024, we renewed the ISO 14001:2015 certification for its environmental management system, reflecting rigorous audit protocols and continual improvement cycles. All employees have been trained in the ISO 14001-certified environmental management system, and 78 percent of critical suppliers have signed HTL Biotechnology’s Responsible Purchasing Charter.These results reflect HTL Biotechnology’s structured and proactive approach to reducing its environmental footprint while maintaining the highest standards of quality and compliance.HIGHLIGHTS// Sustainability embedded in strategic vision/strong CSR roadmap with measurable progress/reduction in greenhouse gas emissions/responsible sourcing 

    Impressions: 3013

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/over-500-million-syringes-of-our-hyaluronic-acid-have-been-safely-used-worldwide

    PharmaCompass
    04 Nov 2025
    Share info Share

    VLOG #PharmaReel

    [Sponsored by another company]

    ReelPharmaAn Illustrious Journey of More Than 4 DecadesAn Illustrious Journey of More Than 4 Decades

    An Illustrious Journey of More Than 4 Decades
    An Illustrious Journey of More Than 4 Decades

    reelAn Illustrious Journey of More Than 4 Decades

    This PharmaReel showcases Granules India, manufacturing generic & high-potent APIs, PFIs & FDFs, and complex MUPS, supported by high volume world-class facilities and approvals from US FDA, EDQM, PMDA and ANVISA, serving 300+ customers in over 80 countries.

    Impressions: 134

    read-more

    DATA COMPILATION #PharmaFlow

    [Sponsored by another company]
    FDA’s December 2025 OPOE list features 784 prescription drugs, 73 OTC drugs

    FDA’s December 2025 OPOE list features 784 prescription drugs, 73 OTC drugs

    This week, PharmaCompass brings you key highlights of the US Food and Drug Administration’s December 2025 list of Off-Patent, Off-Exclusivity Drugs (OPOE) without an approved generic. The OPOE list gets updated every six months.This list highlights drug products that have lost patent protection and regulatory exclusivity, but remain without approved generic competition in the US market. With this list, the FDA hopes to bolster competitiveness in the generics market, improve transparency and encourage the development and submission of abbreviated new drug applications (ANDAs) in markets with little competition.Since December 2021, FDA has been publishing two versions of the OPOE list — one for prescription (Rx) drug products and the other for over-the-counter (OTC) drug products that are approved and marketed under a new drug approval (NDA).  Access the Interactive Dashboard on FDA's December 2025 List of OPOE Drugs (Free Excel)Injectables continue to dominate FDA’s OPOE Rx list; 73 OTC drugs figure in Dec listFDA’s December 2025 OPOE Rx list includes 784 drug products that currently have no approved generics. Out of these, 297 are injectables and 126 are oral solid dosage forms (such as tablets, capsules and modified release forms). In June 2025, the OPOE Rx list had 765 drug products without an approved generic, out of which 304 were injectables, while 109 were oral solid drug forms. The increase in drug products from 765 to 784 from June 2025 to December 2025 was due to the inclusion of additional dosage strengths in the OPOE Rx list. Otherwise, no new drugs were added to the December 2025 OPOE Rx list.The December 2025 OPOE list has 73 OTC drugs, slightly higher than the 69 drugs in the June 2025 list. Among the 73, 21 are oral solid dosage forms.Among the OTC drugs on the December 2025 OPOE list are ibuprofen and ibuprofen sodium (for pain and inflammation), pseudoephedrine hydrochloride and phenylephrine hydrochloride (nasal decongestants), nizatidine and famotidine (for gastroesophageal reflux disease), loratadine, cetirizine hydrochloride and chlorpheniramine maleate (for allergy relief), loperamide hydrochloride (anti-diarrheal), and orlistat (for weight management). Access the Interactive Dashboard on FDA's December 2025 List of OPOE Drugs (Free Excel)FDA fast-tracks initiatives to accelerate market entry of generics, biosimilarsFDA has launched several regulatory initiatives designed to accelerate the market entry of generics and biosimilars. In October 2025, the agency announced a new pilot prioritization program for the review of ANDAs that aims to encourage and reward investment in drug manufacturing, research and development and strengthen the pharmaceutical supply chain in the United States.Separately, FDA has also come out with a new draft guidance that seeks to simplify biosimilarity studies and reduce unnecessary clinical testing. Through a separate initiative, the agency also plans to make it easier for biosimilars to be developed as interchangeable with brand-name biologics, thereby helping patients and pharmacists choose lower-cost options. Access the Interactive Dashboard on FDA's December 2025 List of OPOE Drugs (Free Excel) Our viewThe global generic drugs market was valued at US$ 445.62 billion in 2024 and is projected to reach US$ 728.64 billion by 2034, growing at a compound annual growth rate of 5.04 percent from 2025 to 2034. With several diabetes, immunology, oncology and cardiology drugs slated to face patent expirations this year, and continued pressure on drugmakers to improve affordability, we believe the generic market could grow at an even faster rate in the near term.
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 361

    https://www.pharmacompass.com/radio-compass-blog/fda-opoe

    #PharmaFlow by PHARMACOMPASS
    22 Jan 2026
    Share Share

    NEWS #PharmaBuzz

    [Sponsored by another company]read-more
    read-more
    Zoetis To Host Webcast On Q4 & Full Year 2025 Financial Results
    Zoetis To Host Webcast On Q4 & Full Year 2025 Financial Results

    30 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251230734251/en/Zoetis-to-Host-Webcast-and-Conference-Call-on-Fourth-Quarter-and-Full-Year-2025-Financial-Results

    BUSINESSWIRE
    30 Dec 2025
    Share Share
    Zoetis Joins 44Th J.P. Morgan Healthcare Conference
    Zoetis Joins 44Th J.P. Morgan Healthcare Conference

    18 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251218359796/en/Zoetis-to-Participate-in-the-44th-Annual-J.P.-Morgan-Healthcare-Conference

    BUSINESSWIRE
    18 Dec 2025
    Share Share
    Zoetis Prices $1.75B Convertible Senior Notes Offering
    Zoetis Prices $1.75B Convertible Senior Notes Offering

    16 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251215781686/en/Zoetis-Announces-Pricing-of-%241.75-Billion-Convertible-Senior-Notes-Offering

    BUSINESSWIRE
    16 Dec 2025
    Share Share
    Zoetis Proposes $1.75B Convertible Senior Notes Offering
    Zoetis Proposes $1.75B Convertible Senior Notes Offering

    15 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251214535308/en/Zoetis-Announces-Proposed-%241.75-Billion-Convertible-Senior-Notes-Offering

    BUSINESSWIRE
    15 Dec 2025
    Share Share
    Zoetis Boosts First Quarter 2026 Dividend By 6% Payment Increase
    Zoetis Boosts First Quarter 2026 Dividend By 6% Payment Increase

    11 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251211103020/en/Zoetis-Declares-First-Quarter-2026-Dividend-Board-Approves-6-Payment-Increase

    BUSINESSWIRE
    11 Dec 2025
    Share Share
    Zoetis Gets Health Canada Nod For Portela In Cat Osteoarthritis
    Zoetis Gets Health Canada Nod For Portela In Cat Osteoarthritis

    05 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251204633153/en/Zoetis-Receives-Health-Canada-Approval-for-Portelarelfovetmab-injection-to-Alleviate-Pain-Associated-with-Osteoarthritis-in-Cats

    BUSINESSWIRE
    05 Dec 2025
    Share Share
    Contact Zoetis and get a quotation

    Zoetis is a supplier offers 48 products (APIs, Excipients or Intermediates).

    Find a price of Amoxicillin Trihydrate bulk offered by Zoetis

    Find a price of Bacitracin Methylenedisalicylic Acid bulk offered by Zoetis

    Find a price of Bacitracin Zinc bulk offered by Zoetis

    Find a price of Carprofen bulk offered by Zoetis

    Find a price of Cefovecin bulk offered by Zoetis

    Find a price of Ceftiofur bulk offered by Zoetis

    Find a price of Ceftiofur Sodium bulk offered by Zoetis

    Find a price of Chlortetracycline bulk offered by Zoetis

    Find a price of Chlortetracycline Hydrochloride bulk offered by Zoetis

    Find a price of Cloxacillin Benzathine bulk offered by Zoetis

    Find a price of Cloxacillin Sodium bulk offered by Zoetis

    Find a price of Cypermethrin bulk offered by Zoetis

    Find a price of Danofloxacin Mesylate bulk offered by Zoetis

    Find a price of Decoquinate bulk offered by Zoetis

    Find a price of Dihydrostreptomycin sulfate bulk offered by Zoetis

    Find a price of Dimethyl Sulfoxide bulk offered by Zoetis

    Find a price of Dinitolmid (DOT) bulk offered by Zoetis

    Find a price of Doramectin bulk offered by Zoetis

    Find a price of Epsiprantel bulk offered by Zoetis

    Find a price of Estradiol Benzoate bulk offered by Zoetis

    Find a price of Flumethasone bulk offered by Zoetis

    Find a price of Isoflupredone Acetate bulk offered by Zoetis

    Find a price of Lasalocid A Sodium bulk offered by Zoetis

    Find a price of Levamisole bulk offered by Zoetis

    Find a price of Maropitant bulk offered by Zoetis

    Find a price of Melengestrol Acetate bulk offered by Zoetis

    Find a price of Morantel Tartrate bulk offered by Zoetis

    Find a price of Moxidectin bulk offered by Zoetis

    Find a price of Neomycin Sulfate bulk offered by Zoetis

    Find a price of Oclacitinib Maleate bulk offered by Zoetis

    Find a price of Oxytetracycline Dihydrate bulk offered by Zoetis

    Find a price of Oxytetracycline Hydrochloride bulk offered by Zoetis

    Find a price of Pyrantel Pamoate bulk offered by Zoetis

    Find a price of Ractopamine Hydrochloride bulk offered by Zoetis

    Find a price of Recombinant Human Growth Hormone bulk offered by Zoetis

    Find a price of Sarolaner bulk offered by Zoetis

    Find a price of Selamectin bulk offered by Zoetis

    Find a price of Spectinomycin HCl bulk offered by Zoetis

    Find a price of Sulfadimidine bulk offered by Zoetis

    Find a price of Testosterone Propionate bulk offered by Zoetis

    Find a price of Toceranib Phosphate bulk offered by Zoetis

    Find a price of Trenbolone bulk offered by Zoetis

    Find a price of Tulathromycin bulk offered by Zoetis

    Find a price of Water bulk offered by Zoetis

    Find a price of MANUFACTURING OPERATIONS bulk offered by Zoetis

    Find a price of MEDICATED FEED bulk offered by Zoetis

    Find a price of bulk offered by Zoetis

    Find a price of LAIDLOMYCIN PROPIONATE POTASSIUM SALT bulk offered by Zoetis

    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.